Medications remain crucial in treating mood disorders like depression and bipolar disorder. Recent advancements offer new hope for many patients.
In 2025, the FDA approved esketamine nasal spray for adults with major depressive disorder who haven't responded to other treatments. Esketamine targets the glutamate system, which plays a role in depressive symptoms.
Studies show ketamine and esketamine treatments significantly reduce suicide-related emergency department visits. This highlights their potential in crisis situations. These treatments offer hope and healing for many.